Zydus partners with Bioeq to market macular degeneration drug NUFYMCO in US

Zydus Lifesciences Limited on Tuesday, December 23, announced a strategic partnership with Swiss biopharmaceutical company Bioeq AG for the licensing, supply and commercialisation of NUFYMCO, an interchangeable

biosimilar to Lucentis (ranibizumab), in the US market.

Under the agreement, Zydus Lifesciences Global FZE, a wholly-owned subsidiary of Zydus Lifesciences Limited based in the United Arab Emirates, will commercialise the product in the US, while Bioeq will be responsible for its development, manufacturing, regulatory registration and supply.

NUFYMCO is a vascular endothelial growth factor (VEGF) inhibitor, and its Biologics License Application (BLA) had received approval from the US Food and Drug Administration (FDA) on December 18, 2025. Ranibizumab is used to treat neovascular (wet) age-related macular degeneration (AMD). It is also used in diabetic patients who have diabetic macular edema (DME).

Speaking on the development, Managing Director of Zydus Lifesciences Limited Sharvil P Patel said, “Through this partnership, we will leverage our combined expertise and resources to accelerate organisational growth while ensuring maximum value to patients through an expanded access to affordable ophthalmology care.”

Thiemo Schreiber, Vice President, Commercial, Bioeq, stated, “This latest addition to our portfolio reflects Bioeq’s advanced expertise in developing complex biosimilar medicines for highly regulated markets. Our partnership with Zydus will leverage its extensive distribution network and strong sales and marketing capabilities across the US to broaden treatment options for patients.”

ALSO READ | Zydus Life's US arm gets FDA nod for paediatric drug CUTX-101 NDA resubmission

The partnership marks an expansion of Zydus’ biosimilar portfolio the US and follows its recent collaboration with Formycon AG for a biosimilar of Keytruda (pembrolizumab).

Share of the Zydus Lifesciences Limited closed at ₹929.45 on the NSE, up 1.23% today, December 23.

ALSO READ | Emcure Pharma's Gujarat plant gets all-clear from FDA